VANCOUVER, May 1 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced that it has received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) to begin marketing sizes 3-0 and 4-0 of its Quill
Self-Retaining System (SRS) Polydioxanone (PDO) product line. The Quill SRS
PDO is a longer-lasting absorbable suture, which is typically used for deeper
tissue closures. These smaller diameter sizes incorporate a new design for
better holding strength and expand the number and scope of procedures that can
be done with the Quill SRS product.